ImmunityBio, Inc. (IBRX) dividend history

IBRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30

$6.02−0.05 (-0.82%)

Close on Nov 13, 2026Market cap $6.38BP/E –Yield –

Dividends

No dividend per share appears in ImmunityBio's annual filings since fiscal 2012.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IBRX.

Revenue growth121.2% · median 17.9%

Gross margin98.8% · median 63.7%

Operating margin-150.2% · median -60.8%

Net margin-607.8% · median -58.2%

Advertisement
300 × 250

See a number that looks wrong?